A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers

Single-centre, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Dose of 14C-labeled RO4917523 and an Intravenous Tracer Dose of 13C-labeled RO4917523 in Healthy Male Volunteers

This single-center, open-label study will assess the excretion balance, pharmacokinetics and metabolism of oral [14C]-labeled RO4917523 in healthy male volunteers. Subjects will receive a single oral dose of [14C]-labeled RO4917523 and an intravenous tracer dose of [13C]-labeled RO4917523 on Day 1. In-clinic period will be up to 18 Days. Anticipated time on study is up to 15 weeks.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteer
• Intervention / Treatment: Drug: RO4917523; Drug: RO4917523

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Zuidlaren, Netherlands, 9471 GP

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Male adults, 18 to 65 years of age inclusive
• Body mass index (BMI) 18.0 to 32.0 kg/m2
• Healthy, as judged by a physician on the basis of a medical history, general physical examination, laboratory tests, vital signs and 12-lead ECG
• Medical history without major pathology
• Agree to use two effective methods of contraception with their partners, including one barrier method (e.g. condom) throughout the study and for up to 3 months after the last dose of study drug

Exclusion Criteria:

• History of relevant drug and or food allergies
• Smoking (within 60 days prior to drug administration until the follow-up visit)
• History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
• Participation in a drug study within 60 days preceding first administration of study drug; participation in more than 3 other drug studies within 10 months preceding the first administration of study drug
• Infrequent bowel movements (less than once per 2 days)
• Participation in another ADME study with a radiation burden >0,1 mSv in the period of 1 years before the start of the study
• Positive screen for drugs of abuse
• Average intake of more than 24 units of alcohol per week
• Positive for hepatitis B, hepatitis C or HIV infection

Study Plan

How is the study designed?

Design Details

• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: [14C]-labeled RO4917523	Drug: RO4917523; [14C]-labeled RO4917523, single oral dose; Drug: RO4917523; [13C]-labeled RO4917523, single intravenous tracer dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Elimination: urinary and fecal recovery of total radioactivity	Pre-dose and up to approximately Day 18 post-dose
Plasma concentrations of RO4917523	Pre-dose and up to approximately Day 18 post-dose

Secondary Outcome Measures

Outcome Measure	Time Frame
Metabolites of RO4917523 in plasma/urine/blood pellet/feces based on radioactive metabolic profiling	Pre-dose and up to approximately Day 18 post-dose
Absolute bioavailability: Area under the concentration-time curve (AUC)	Pre-dose and up to approximately Day 18 post-dose

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start: April 1, 2012
• Primary Completion (Actual): May 1, 2012
• Study Completion (Actual): May 1, 2012

Study Registration Dates

• First Submitted: May 4, 2012
• First Submitted That Met QC Criteria: May 4, 2012
• First Posted (Estimate): May 7, 2012

Study Record Updates

• Last Update Posted (Estimate): November 2, 2016
• Last Update Submitted That Met QC Criteria: November 1, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Other Study ID Numbers: BP27854; 2011-004597-28 (EudraCT Number)